In plain language
In mock septal defect closures on a 3D-printed heart phantom, electromagnetic catheter tracking cut fluoroscopy radiation dose by about 62% compared with fluoroscopy alone, with slightly longer procedures. This is a phantom dose result, not a health outcome.
At a glance
- Type of study
- Original research, Phantom or simulation study
- Who was studied
- Phantom or simulation (no people), Interventional cardiologists
- Summary based on
- the abstract
What it found
Electromagnetic tracking-based image guidance gave a lower radiation dose per mock septal occluder procedure than fluoroscopy-only guidance.
Key figures: 1.26 mSv vs 3.33 mSv per procedure
Average dose saving with the image-guided method was about 62%.
Key figures: 2.07 mSv or 62 %
The dose reduction came with a modest increase in procedure time.
Limits to keep in mind
Mock procedures on a 3D-printed phantom by a single expert clinician, with an unstated number of procedures; the abstract does not specify whether dose refers to patient or staff, and no health outcomes were measured.
Related research summaries
- Radiation Exposure, Training, and Safety in Cardiology (2024, Narrative review)
- Ionizing Radiation in Interventional Cardiology and Electrophysiology (2019, Narrative review)
- Reduced radiation exposure in the cardiac catheterization laboratory with a novel vertical radiation shield (2019, Prospective cohort study)
- Patient And Staff Doses In Paediatric Interventional Cardiology Derived From Experimental Measurements With Phantoms (2015, Phantom or simulation study)
- Feasibility of using ultra-low pulse rate fluoroscopy during routine diagnostic coronary angiography (2018, Retrospective cohort study)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.